{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:21Z","timestamp":1753877661117,"version":"3.41.2"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prostate and colorectal adenocarcinoma are among the most common primary cancer diagnoses in the United States, with 29% of new cancer diagnoses among adult men in 2024 expected to arise from the prostate and another 15% across men and women being colorectal in origin. Given therapeutic advancements leading to improved survival, individuals with prostate cancer have the highest estimated probability of concurrent secondary primary malignancy. This represents a clinical dilemma as the treatment for each is distinct and impacted by histology, stage, and molecular findings. Herein, we describe a patient with significant comorbidities, found to have simultaneous metastatic prostate and colorectal adenocarcinomas, who achieved sustained complete remission of liver and lung metastases with a chemohormonal regimen.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf026","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:58:01Z","timestamp":1741625881000},"source":"Crossref","is-referenced-by-count":0,"title":["Managing elderly patients with dual metastatic cancers\u2014navigating diagnostic and treatment challenges"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1038-6787","authenticated-orcid":false,"given":"Zane","family":"Gray","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Levonyak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]},{"name":"Hematology-Oncology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6728-0009","authenticated-orcid":false,"given":"Richard","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Balani","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6962-0171","authenticated-orcid":false,"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]},{"name":"Hematology-Oncology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390-8852 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2025031016574533900_CIT0001","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.2147\/OTT.S110595","article-title":"Prostate cancer patients may have an increased risk of coexisting advanced colorectal neoplasms","volume":"9","author":"Ko","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2025031016574533900_CIT0002","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1385\/IJGC:34:1:49","article-title":"Increased cumulative incidence of prostate malignancies in colorectal cancer patients","volume":"34","author":"Ozden","year":"2003","journal-title":"Int J Gastrointest Cancer"},{"key":"2025031016574533900_CIT0003","doi-asserted-by":"publisher","first-page":"S873","DOI":"10.14309\/00000434-201810001-01519","article-title":"Prostate metastasis presenting as primary colon cancer: 1519","volume":"113","author":"Lopez","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2025031016574533900_CIT0004","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12935-018-0672-2","article-title":"Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis","volume":"18","author":"Song","year":"2018","journal-title":"Cancer Cell Int."},{"key":"2025031016574533900_CIT0005","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.chest.2019.05.007","article-title":"Cannonball-like lung nodules in a patient with a colorectal tumor","volume":"156","author":"Scamporlino","year":"2019","journal-title":"Chest"},{"key":"2025031016574533900_CIT0006","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"2025031016574533900_CIT0007","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.2147\/OTT.S305039","article-title":"Durable clinical response to immune and targeted therapies in an elderly man with synchronous gastric (HER2+) and bladder cancers: case report and literature review","volume":"14","author":"Tian","year":"2021","journal-title":"OncoTargets Ther"},{"key":"2025031016574533900_CIT0008","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1200\/OP.23.00263","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO Guideline Questions and Answers","volume":"19","author":"Williams","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2025031016574533900_CIT0009","doi-asserted-by":"publisher","first-page":"4986365","DOI":"10.1155\/2020\/4986365","article-title":"BRCA mutations in prostate cancer: prognostic and predictive implications","volume":"2020","author":"Messina","year":"2020","journal-title":"J Oncol"},{"key":"2025031016574533900_CIT0010","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur Urol"},{"key":"2025031016574533900_CIT0011","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ijc.33306","article-title":"Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer","volume":"148","author":"Slootbeek","year":"2021","journal-title":"Int J Cancer"},{"key":"2025031016574533900_CIT0012","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdg342","article-title":"Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients","volume":"14","author":"Droz","year":"2003","journal-title":"Ann Oncol"},{"key":"2025031016574533900_CIT0013","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/COC.0b013e3181d6b453","article-title":"Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients","volume":"34","author":"Gasent Blesa","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"2025031016574533900_CIT0014","doi-asserted-by":"publisher","first-page":"S962","DOI":"10.1016\/j.annonc.2024.08.1700","article-title":"1619P Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: results from the biomarker-driven, randomised, outcome-adaptive ProBio trial","volume":"35","author":"Kristiansen","year":"2024","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf026\/62368962\/oyaf026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf026\/62368962\/oyaf026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:58:03Z","timestamp":1741625883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf026\/8068850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf026","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyaf026"}}